LEVITACCORD TABLETS

Država: Australija

Jezik: engleski

Izvor: Department of Health (Therapeutic Goods Administration)

Kupi sada

Preuzimanje Uputa o lijeku (PIL)
24-06-2024
Preuzimanje Svojstava lijeka (SPC)
24-06-2024

Aktivni sastojci:

Levetiracetam

Dostupno od:

Accord Healthcare Pty Ltd

Razred:

Medicine Registered

Uputa o lijeku

                                LEVITACCORD TABLETS 
CONSUMER MEDICINE INFORMATION
                                
                                             
                                             
                                        
  Version 2
 
2012                                            
                                             
                                 Page: 1 of 5
 
 
 
 
 
 
 
  
 
LEVITACCORD TABLETS 250 MG/500 MG/1000 MG  
(Levetiracetam tablets 250mg/500 mg/1000 mg) 
levetiracetam 
CONSUMER MEDICINE INFORMATION                       
                                  
 
WHAT IS IN THIS LEAFLET  
 
This leaflet answers some 
common questions about 
Levitaccord tablets. 
It does not contain all the 
available information. It does not 
take the place of talking to your 
doctor or pharmacist. 
All medicines have risks and 
benefits. Your doctor has 
weighed the risks of you taking 
Levitaccord tablets against the 
benefits they expect it will have 
for you. 
IF YOU HAVE ANY CONCERNS ABOUT 
TAKING THIS MEDICINE, ASK YOUR 
DOCTOR OR PHARMACIST. 
KEEP THIS LEAFLET WITH THE 
MEDICINE. 
You may need to read it again. 
 
WHAT LEVITACCORD 
TABLETS ARE USED FOR  
 
Levitaccord tablets are used to 
control epilepsy. 
Epilepsy is a condition where 
you have repeated seizures. 
There are many different types of 
seizures, ranging from mild to 
severe. 
Levitaccord tablets belong to a 
group of medicines called 
antiepileptics. 
These medicines are thought to 
work by controlling brain 
chemicals which send signals to 
nerves so that seizures do not 
happen. 
Levitaccord tablets may be used 
alone or in combination with 
other medicines, to treat your 
condition. 
Your doctor may have prescribed 
Levitaccord tablets in a
                                
                                Pročitajte cijeli dokument
                                
                            

Svojstava lijeka

                                Levitaccord Tablets (Levetiracetam tablets 250/500/1000 mg)      
                    Version: 2 
 
 
2012                                            
                                             
                 Page: 1 of 28
     
 
PRODUCT INFORMATION 
LEVITACCORD TABLETS 250 MG/500 MG/1000 MG 
(LEVETIRACETAM TABLETS 250/500/1000 MG) 
 
NAME OF THE MEDICINE  
Levetiracetam 
 
Structural formula:  
 
 
Levetiracetam 
 
Chemical name:-  (_S_)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide. 
 
CAS number: 102767-28-2 
 
Levetiracetam has a molecular formula of C
8
H
14
N
2
O
2
 and a molecular weight of 170.21. 
 
DESCRIPTION  
Levetiracetam is a white to off white powder with a faint odour and a
bitter taste. It is 
very soluble in water (104 g/100 mL). It is freely soluble in
chloroform (65.3 g/l00 mL) 
and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL),
sparingly soluble 
in acetonitrile (5.7 g/100 mL) and practically insoluble in
n-hexane. 
 
Levitaccord Tablets 250 mg are white to off white, oval biconvex,
film coated tablets, 
debossed ‘L 64’ and breakline on one side and plain on the other
side.  
 
Levitaccord Tablets 500 mg are yellow coloured, oval biconvex,
film coated tablets, 
debossed ‘L 65’ and breakline on one side and plain on the other
side.  
 
Levitaccord Tablets (Levetiracetam tablets 250/500/1000 mg)      
                    Version: 2 
 
 
2012                                            
                                             
                 Page: 2 of 28
     
 
Levitaccord Tablets 1000 mg are white to off white, oval biconvex,
film coated tablets, 
debossed ‘L 67’ and breakline on one side and plain on the other
side.  
 
Levitaccord tablets contain the following excipients: croscarmellose
sodium, povidone, 
colloidal anhydrous silica and magnesium stearate.
                                
                                Pročitajte cijeli dokument
                                
                            

Upozorenja za pretraživanje vezana za ovaj proizvod

Pogledajte povijest dokumenata